At a glance
ClinicalIndex Comparison RecordN/ACompleted· 21 enrolled
Drug / intervention
ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapyprocedure
Likely dose
Ultrasound-guided percutaneous radiofrequency ablation with endocrine therapyAI-extracted
Key inclusion· 4
- ✓Age over 70 years
- ✓Estrogen receptor-positive breast tumors
- ✓Not a surgical candidate
- ✓Life expectancy greater than 6 months
Key exclusion· 5
- ✕Pacemaker present
- ✕Tumor >30 mm on ultrasound or located <10 mm from skin, nipple, or pectoral muscle
- ✕Coagulation disorders
- ✕Contraindication to MRI or contrast-enhanced CT
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Radiofrequency of Breast Cancers : Pilot Study in Non Surgical Patients
In Brief
A clinical study evaluating ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy for Breast Cancer. Completed, enrolled 21 participants across 1 site.
Detailed Summary
To determine the efficacy and tolerance of ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy in elderly patients with breast cancer who decline or are not candidates for surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesFrance
Collaborators--
Timeline
N/ACompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2004
First PostedSep 2005
Primary CompletionDec 2010
Study CompletionDec 2011
TodayJul 2026
First PostedSep 21, 2005
Enrollment StartJan 1, 2004
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 20.8 years ago
Interventions
ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapyprocedure
ultrasonography (US)-guided percutaneous radiofrequency (RF) ablation with endocrine therapy